ASX ANNOUNCEMENT

EXOPHARM'S LEAP™ EXOSOME TECHNOLOGY RECEIVES FIRST NATIONAL PATENT

- Exopharm has been granted a patent for its LEAP technology by Russia's Patent Office.
- The patent underpins a core Exopharm technology that enables the large-scale purification of exosome medicines.
- LEAP patent applications continue to progress through national phases in twelve jurisdictions.

3 June 2021

Melbourne, Australia: Exopharm (ASX:EX1) has been granted its first patent for its Ligand-based Exosome Affinity Purification (LEAP) technology from Russia.

The grant of this patent is a constructive signal to the prosecution of the related patent family in the other eleven jurisdictions where the patent applications are progressing through national phases. This includes the United States wherein a successful Fast Track application has been approved by the US Patent and Trademark Office, resulting in expedited examination and the prospects for early grant in that jurisdiction.

The company has today received advice of 'grant' by the Russian Patent Office for the patent entitled '*Methods and compositions for purification or isolation of microvesicles and exosomes*', numbered 2748234, with an expiry date of 22 December 2037. Exopharm was able to address all concerns raised by the Russian office resulting in the granting of all claims applied for in the original application.

"This is an incredibly important result for Exopharm," says LEAP co-inventor and Exopharm CEO Dr Ian Dixon. "For the first time, our broad claims around the novel use of chromatography for exosome purification have been granted at the country-level. These claims are the same we are actively progressing in key markets across North America, Europe and Asia."

The granted patent covers a core Exopharm technology that enables the efficient exosome extraction and purification needed to manufacture exosome-based medications at clinical and then pharmaceutical grade and scale.

"Our exosome technology platform enables our partners and licensees to achieve commercial scale manufacturing. From the clinical validation of the safety and scalability of LEAP through our recent human trial, to the technology transfer efforts we are making with prospective licensees, all signs point to LEAP as the standout purification approach for exosome medicines," says Deputy CEO and Chief Commercial Officer Dr Chris Baldwin.

By the Board - this announcement has been authorised for release by the board.

EXOPHARM LIMITED ACN: 163 765 991 ASX:EX1
Address: Suite 201, 697 Burke Road Camberwell 3124
Email: info@exopharm.com Web: www.exopharm.com

Company and Media Enquiries:

Join our mailing list to receive updates:
mailto:info@exopharm.comhttp://exo.ph/ExoMails
www.exopharm.com
P: +61 (0)3 9111 0026

Rudi Michelson
Monsoon Communications
Tel: +61 (0)3 9620 3333

ABOUT EXOPHARM

Exopharm (ASX:EX1) is a clinical-stage biopharmaceutical company using exosomes to deliver a new class of transformative medicines and generate revenue from multiple partnership deals. Exosomes are seen by the Biopharma industry as a highly differentiated platform with the potential to enhance tissue delivery for a variety of payloads like mRNA and proteins – part of the global market for drug delivery systems which is growing at a compound annual growth rate (CAGR) of 5% and valued at around US$170 billion in 2021.

For some medicines, exosomes are an alternative and superior means for delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell penetrating peptides, viral vectors and liposomes.

Exopharm's LEAP technology solves the challenge of purifying clinical-grade exosomes at large scale and low cost.

Exopharm also has two exclusive proprietary technologies that allow advanced customisation of exosomes – the LOAD technology improves loading of nucleic medicines into exosomes and the EVPS technology allows exosomes to be directed towards selected cell types.

Exopharm uses variations and combinations of LOAD and EVPS to enable its Biopharma partners to improve delivery of their drug candidates and help them design and test new exosome medicines aimed at treating a wide scope of medical problems including neurological disease, infectious disease, cancer, and fibrosis.

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements which incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets', 'aims', 'plans' or 'expects'. These statements are based on an evaluation of current corporate estimates, economic and operating conditions, as well as assumptions regarding future events. These events are, as at the date of this announcement, expected to take place, but there cannot be any guarantee that such events will occur as anticipated or at all given that many of the events are outside of Exopharm's control.

INHERENT RISKS OF INVESTMENT IN BIOTECHNOLOGY COMPANIES

There are a number of inherent risks associated with the development of biopharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology. Companies such as Exopharm are dependent on the success of their research and development projects and on the ability to attract funding to support these activities. Investment in research and development projects cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore, investment in companies specialising in drug development must be regarded as highly speculative. Exopharm strongly recommends that professional investment advice be sought prior to such investments.